Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas

BACKGROUND: There are currently no United States Food and Drug Administration approved molecularly matched therapies for sarcomas except gastrointestinal stromal tumors. Complicating this is the extreme diversity, heterogeneity, and rarity of these neoplasms. Few therapeutic options exist for relaps...

Descripción completa

Detalles Bibliográficos
Autores principales: Groisberg, Roman, Hong, David S., Holla, Vijaykumar, Janku, Filip, Piha-Paul, Sarina, Ravi, Vinod, Benjamin, Robert, Patel, Shreyas Kumar, Somaiah, Neeta, Conley, Anthony, Ali, Siraj M., Schrock, Alexa B., Ross, Jeffrey S., Stephens, Philip J., Miller, Vincent A., Sen, Shiraj, Herzog, Cynthia, Meric-Bernstam, Funda, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503611/
https://www.ncbi.nlm.nih.gov/pubmed/28424409
http://dx.doi.org/10.18632/oncotarget.16845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503611/
https://www.ncbi.nlm.nih.gov/pubmed/28424409
http://dx.doi.org/10.18632/oncotarget.16845

Ejemplares similares